Managing Advanced Prostate Cancer in the COVID-19 Era: What Do Oncologists Need to Know?

The treatment of advanced prostate cancer has changed significantly in recent years, from the introduction of chemotherapy and androgen inhibitors to the metastatic hormone-sensitive prostate cancer (HSPC) setting, to the recognition of non-metastatic castration-resistant prostate cancer (nmCRPC) as a disease state with multiple effective treatment options. However, the biggest change to how patients with prostate cancer are managed has come in the past year with the COVID-19 pandemic. Because patients with cancer are at increased risk of complications due to COVID-19 infection, their care must be prudently managed during this time. While delaying prostate cancer treatment is an option for some patients, telemedicine has emerged as a potential alternative to in-person care that reduces risk of Sars-CoV-2 transmission while maintaining standards and quality of care while patients wait for access to vaccines.

Managing Advanced Prostate Cancer in the COVID-19 Era: What Do Oncologists Need to Know? Will provide oncologists with the most up-to-date evidence-based information and expert guidance on selecting and sequencing therapies in advanced prostate cancer and managing patient care during the COVID-19 pandemic.

Target Audience

The intended audience for this educational initiative is oncologists and other clinicians involved in the management of patients with prostate cancer.

Learning Objectives

The proposed initiative is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine. This program is designed to address ACPE competencies, including foundational knowledge, essentials for practice and care, and approaches to practice and care.

At the conclusion of this education, participants should be able to:

  • Evaluate current and emerging treatments for patients with advanced prostate cancer based on clinical trial safety and efficacy data
  • Develop patient-personalized treatment plans for advanced prostate cancer across all stages of disease
  • Integrate consensus recommendations for the safe and effective management of prostate cancer during the COVID-19 pandemic
  • Adopt recommended practices for appropriate integration of telemedicine into prostate cancer care  

Additional Information

Rockpointe Corporation
Course summary
Available credit: 
  • 1.00 MOC
  • 1.00 MOC II
  • 1.00 AMA PRA Category 1 Credit
Course opens: 
Course expires: 

Steven Ludlow, PharmD, BCOP, BCPS is a medical oncology clinical pharmacy specialist at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He works in inpatient medical oncology and internal medicine services. He has been in clinical practice for 19 years, with 13 years at Moffitt Cancer Center. His personal areas of interest include immunology, immunotherapy, melanoma and GU oncology. He is originally from Toledo Ohio and attended the University of Toledo and the Ohio State University.

Alicia K. Morgans, MD, MPH is an Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. She specializes is investigating complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications of prostate cancer survivorship. She also studies the way patients and their care teams make treatment decision making for metastatic prostate cancer. She has been awarded several Prostate Cancer Foundation grants to investigate the cognitive effects and quality of life effects of hormonal treatments in advanced prostate cancer, and a Department of Defense grant to assess treatment decision making. She serves on the advanced and localized guidelines committees of the American Urologic Association, and is a member of the cardio-oncology committee of American Heart Association. She also acts as the Principal Investigator for multiple therapeutic and non-interventional prostate cancer and bladder cancer clinical trials at Northwestern University.

Scott T. Tagawa, MD, MS, FACP is a Professor of Medicine and Professor of Medicine in Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center. After earning his BS from Georgetown University, Dr. Tagawa received his MD at the University of Southern California School of Medicine. After completing his Internship and Residency training there, he became Chief Resident and subsequently underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years. He had the opportunity to train with international leaders in Genitourinary (GU) Oncology. In 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials. He was recruited to Weill Cornell Medical College in 2007. His research covers clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, bladder, and kidney cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development in prostate cancer with a particular interest in prostate-specific membrane antigen (PSMA) theranostics. Dr. Tagawa also serves as Associate Director of Clinical Research for the Division of Hematology and Medical Oncology and Chair of the Feasibility Committee for cancer research. He is the WCM principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. He is currently Chair Elect of the Clinical Practice Guidelines Committee of the American Society of Clinical Oncology (ASCO). Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies, and has been named on multiple “top doctor” award lists.

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

Program Faculty
The faculty, authors and content developers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Steven Ludlow, PharmD, BCOP, BCPS: Nothing to disclose
Alicia K. Morgans, MD, MPH: Consultant/Independent Contractor: Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Blue Earth, Clovis, Dendreon, Genentech, Janssen, Myovant, Sanofi, Seattle Genetics; Grant/Research Support: Bayer, Sanofi, Seattle Genetics 
Scott T. Tagawa, MD, MS, FACP: Grant/Research Support: Advanced Accelerator Applications/Novartis, Abbvie, Amgen, Astellas, AstraZeneca, Atlab, Aveo, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Dendreon, Endocyte, Genentech, Immunomedic, Inovio, Janssen, Karyopharm, Lilly, Medivation, Merck, Millennium, Newlink, Progenics, Rexahn, Sanofi, Seattle Genetics; Honoraria: Advanced Accelerator Applications/Novartis, Abbvie, Amgen, Bayer, Blue Earth Diagnostics, Clovis, Dendreon, Eisai, Endocyte, Genentech, Genomic Health, Immunomedics, Janssen, Karyopharm, Medivation/Astellas, POINT Biopharma, Pfizer, QED Therapeutics, Sanofi, Seattle Genetics, Tolmar 
Planners and Managers
The planners and mangers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:  
Chelsey Goins PhD: Nothing to disclose
Content Reviewers
The content reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Lindsay Scott, PT, DPT, ATC: Nothing to disclose

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME/CPE credit or the evaluation, please email [email protected].

 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

 Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice         relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Improving Rheumatoid Arthritis Care: Understanding the Latest Approvals and Treatment Strategies  has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Family Medicine

The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

For information about this continuing pharmacy education (CPE) activity, please email: [email protected].

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 contact hour (0.10 CEUs) of continuing education credit (UAN number 0418-9999-21-003-H01-P).

This is an application based activity.

Available Credit

  • 1.00 MOC
  • 1.00 MOC II
  • 1.00 AMA PRA Category 1 Credit
Please login or register to take this course.

This course is offered through Rockpointe. 

To take this course you will be redirected to Rockpointe's website. You must login or create an account with Rockpointe in order to complete this activity. 

Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!